NORYVA
Body goals: the most advanced human data in the range.
10 mg
This is the most explored reference for weight loss and appetite control. Published trials measured it in real people, followed for several months.
The same reference, in pen format
The molecule is delivered in a sealed cartridge, inside a refillable anodised aluminium pen. It is not an accessory to add on: it is the other way of ordering the same reference, at its own price.
Everyone promises weight loss. Why believe you?
Because we promise nothing. Published phase 2 trials measured, in people followed for several months, substantial weight loss and reduced hunger. “Phase 2” means measured, not finished — and that is exactly what we write.
It is the most advanced reference in the range on the human-data side. Published trials measured, in people followed for several months, substantial weight loss, less hunger and smaller amounts eaten. These are phase 2 trials: real measurements on real people, but not a completed file.
Retatrutide is a synthetic peptide designed to act on three receptors at once: GIP, GLP-1 and the glucagon receptor. It appears in the literature under the code LY3437943.
All three receptors take part in metabolic regulation. Acting on the three together rather than on one is precisely what this molecule is used to study.
Proposed mechanism: simultaneous agonism of the GIP, GLP-1 and glucagon receptors. What acting on three pathways at once produces cannot be deduced from what each does separately.
The phase 2 trials are published, and they measured. In the trial published in the New England Journal of Medicine in 2023, mean weight change reached −17.5% at 24 weeks and −24.2% at 48 weeks on the 12 mg dose, against −2.1% on placebo. A separate phase 2 analysis reports reduced overall appetite, less hunger and lower daily calorie intake than placebo from the first month. These results concern specific endpoints, in specific populations, over specific durations, under medical supervision and at protocol-defined doses: they transfer neither to other endpoints, nor to other people, nor to use outside that setting.
Published preclinical work on the molecule's affinity and activity at the three receptors.
Investigational molecule. No marketing authorisation, in any country. Clinical development is not complete, and a phase 2 result is not a conclusion. The long-term tolerability profile is not established.
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
Investigational molecule. No marketing authorisation, in any country. Clinical development is not complete, and a phase 2 result is not a conclusion. The long-term tolerability profile is not established.
Conversion not published
How a graduation on the NORYVA pen maps to a volume depends on its mechanism. Its technical sheet is not on file: no conversion is shown until the manufacturer confirms it. We would rather write that than assume it.